Look back at pharma news in week to December 14

15 December 2018

By Barbara Obstoj-Cardwell. Editor

In terms of boardroom changes news last week, Gilead Sciences’ poaching of Roche Pharma head as its new chief executive attracted a great deal of attention. On the clinical trial front, there were disappointments for AstraZeneca, which reported another failure with its immuno-oncology drug Imfinzi, and for Axovant Sciences, which is dropping further development of its neurological candidate nelotanserin due to a Phase II failure. Meantime, on deal-making, despite its own failures in the Alzheimer’s space, Eli Lilly has entered into a licensing agreement to take over AC Immune’s investigational drug ACI-3024.

Gilead looks to a brand new day in cancer

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK